Scientists are developing dog weight loss drugs that work like Ozempic in humans, and they could be on the market as soon as ...

Vivani Medical announced that it brought in $10 million in equity financing as it progresses its drug delivery technology.

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

Vivani Medical ( ($VANI) ) has shared an update. On August 11, 2025, Vivani Medical entered into a Share Purchase Agreement to sell 7,936,507 ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTMimplant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met t ...

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection.